Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the 'Real-Life' Setting

• Egile Nagusiak: Moran Gadot (Egilea), Ido Arad (Egilea), Eshetu G. Atenafu (Egilea), Meital Levartovsky (Egilea), Orith Portnoy (Egilea), Tima Davidson (Egilea), Rachel Schor-Bardach (Egilea), Raanan Berger (Egilea), Raya Leibowitz (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Immune checkpoint inhibitors (ICIs) are now the standard of care for metastatic urothelial carcinoma (mUC) patients. Our aim was to describe the activity of ICIs in mUC and find the clinical parameters associated with response. This is a retrospective, single-center chart review of mUC patients rece...